Lungs News and Research

RSS

Significant gaps in public awareness about cardiovascular risks from tobacco use, secondhand smoke

A report released today at the World Heart Federation World Congress of Cardiology in Dubai reveals significant gaps in public awareness regarding the cardiovascular risks of tobacco use and secondhand smoke. The report, entitled "Cardiovascular harms from tobacco use and secondhand smoke", was commissioned by the World Heart Federation and written by the International Tobacco Control Project (ITC Project), in collaboration with the Tobacco Free Initiative at the World Health Organization.

21 Apr 2012

Scientists discover tumor-targeting neural stem cells

Could engineered human stem cells hold the key to cancer survival? Scientists at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have discovered that neural stem cells possess the innate ability to target tumor cells outside the central nervous system. This finding, which was demonstrated successfully on breast cancer cells, was recently published in leading peer reviewed journal, Stem Cells.

21 Apr 2012

Results from Boehringer Ingelheim's afatinib Phase III lung cancer trial

Highly anticipated results from LUX-Lung 3, the pivotal Phase III lung cancer trial investigating Boehringer Ingelheim's front running oncology investigational compound, the ErbB Family Blocker afatinib, in patients with EGFR mutations, will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012.

21 Apr 2012

Updated results from CircuLite’s Synergy miniature ventricular support system clinical study

CircuLite, Inc. today announced that updated clinical data related to the Synergy miniature ventricular support system was presented in two oral presentations and one poster session at the International Society for Heart and Lung Transplantation's 32nd Annual Meeting and Scientific Sessions (ISHLT) in Prague, Czech Republic.

21 Apr 2012

Possibility to render cancer tumours harmless without affecting other cells

New research findings show how it may be possible to render cancer tumours harmless without affecting the other cells and tissues in the body. The findings apply to cancers including breast, lung and bowel cancer. The study was carried out at Lund University in Sweden.

20 Apr 2012

Longer looks: Rushed medicine; Exercising your way to a smarter brain

Something in the world of medicine is seriously amiss. Unhappy patients gripe about their doctors' brusque manner and give them bad marks on surveys and consumer websites like HealthGrades and Angie's List. They tell tales of being rushed out of the office by harried doctors who miss crucial diagnoses, never look up from their computers during an exam, make errors in prescriptions, and just plain don't listen to their patients. ... And things don't seem much better from the other side of the stethoscope.

20 Apr 2012

Positive data from Synairgen’s SNG001 Phase II trial on asthma

Scientists from the University of Southampton and Synairgen, a respiratory drug development company spun out from the University, can announce positive data from its Phase II clinical trial, into the effectiveness of the drug SNG001 (inhaled interferon beta) for asthma patients.

20 Apr 2012

Developments in mesothelioma treatment presented at 3rd European Lung Cancer Conference

New results presented at 3rd European Lung Cancer Conference in Geneva, Switzerland show important steps being made to improve the diagnosis and treatment of malignant pleural mesothelioma, an aggressive cancer of the outer lining of the lungs caused by asbestos exposure.

19 Apr 2012

NSCLC patients with EGFR mutations benefit from erlotinib-first regimen

Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland.

19 Apr 2012

New studies on personalized lung cancer treatment presented at 3rd ELCC

Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva.

19 Apr 2012

New techniques show promise in detecting early-stage lung cancer

New techniques for identifying lung cancer earlier -including a new type of chest screening, a nanotech 'nose' and a method to examine the cells of the cheek-- are showing substantial promise, according to presentations at the 3rd European Lung Cancer Conference (ELCC) in Geneva.

19 Apr 2012

CRF announces top 10 clinical research achievement awards

Ten outstanding clinical research projects from institutions around the country have been selected to receive the inaugural Clinical Research Forum Top 10 Clinical Research Achievement Awards. The winning projects are compelling examples of the scientific innovation that results from the nation's investment in clinical research that can benefit human health and welfare.

19 Apr 2012

New genetic signature may predict NSCLC patients at risk of relapse

A new genetic signature identified by Spanish researchers may provide doctors with robust and objective information about which patients with early stage lung cancer are at low or high risk of relapse following surgery, investigators report at the 3rd European Lung Cancer Conference in Geneva. Their work also opens new avenues for immunotherapy for lung cancer.

19 Apr 2012

Testosterone may help heart failure patients: Study

The researchers used testosterone patches and injections that improved the breathing and exercise abilities of people with heart failure, a chronic inability of the heart to pump enough blood to the rest of the body. Although most of the study participants were men, the researchers said the results would likely apply to women as well, through much smaller doses of testosterone.

18 Apr 2012

NSCLC drug regimen approved in 2006 does not improve survival for older patients

Analysis of a drug regimen approved by the F.D.A. in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients age 65 years and older who received this regimen did not have improved survival compared to patients who received the standard treatment of carboplatin and paclitaxel alone, according to a study in the April 18 issue of JAMA.

18 Apr 2012

Bevacizumab added to chemotherapy for NSCLC does not improve survival in elderly patients

Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) - an approach approved by the FDA in 2006 - did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.

18 Apr 2012

Flu outbreak at veterans home

State Veterans' Affairs Commissioner Linda Schwartz told The Associated Press that the veterans were taken to Hartford Hospital after a number began complaining of flu-like symptoms. The 18 men live at the Connecticut State Veterans Home in either the Sgt. John L. Levitow Veteran's Health Center or a residential facility.

17 Apr 2012

FDA grants 510(k) clearance for QIAGEN’s molecular detection PCR technology

QIAGEN N.V. today announced that the U.S. Food and Drug Administration (FDA) has granted two 510(k) clearances for its real-time PCR (polymerase chain reaction) instrument Rotor-Gene Q MDx and a compatible test for the detection of Influenza A/B, the artus Infl A/B RG RT-PCR Kit, for in vitro diagnostic use.

From QIAGEN Manchester Limited 17 Apr 2012

UTHealth researcher studies novel cell therapy to prevent GVHD

A researcher at The University of Texas Health Science Center at Houston (UTHealth) is studying a novel cell therapy that could help avoid autoimmune problems after stem cell transplantation, as well as potentially treat other autoimmune diseases.

17 Apr 2012

More than one third of patients with invasive cancer are undertreated for their pain

More than one third of patients with invasive cancer are undertreated for their pain, with minorities twice as likely to not receive analgesics, according to research from The University of Texas MD Anderson Cancer Center.

17 Apr 2012